Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 9, 2007
JNCI Journal of the National Cancer Institute 2007 99(20):1498-1499; doi:10.1093/jnci/djm179
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/20/1498    most recent
djm179v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Seidenfeld, J.
Right arrow Articles by Albertsen, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seidenfeld, J.
Right arrow Articles by Albertsen, P. C.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Competing Risks for Patients With Localized Prostate Cancer

Jerome Seidenfeld, David J. Samson, Peter C. Albertsen

Affiliations of authors: Technology Evaluation Center, Blue Cross and Blue Shield Association, Chicago, IL (JS, DJS); Division of Urology, University of Connecticut Health Center, Farmington, CT (PCA)

Correspondence to: Jerome Seidenfeld, PhD, Technology Evaluation Center, Blue Cross and Blue Shield Association, 225 North Michigan Ave, Chicago, IL 60601 (e-mail: jerome.seidenfeld@bcbsa.com).

The first 10% of the full text of this article appears below.

In health care, as in the rest of life, decisions have consequences. A chosen treatment for prostate cancer can yield benefits, but it can also cause harm. In localized prostate cancer, as in most diseases, baseline characteristics influence the natural history of the disease and thus a treatment's potential for benefit. The most relevant estimates for an individual come from studies involving patients who are similar to the individual selecting treatment.

The recently updated guideline from the American Urological Association lists the following primary treatments for localized prostate cancer: watchful waiting, active surveillance, interstitial brachytherapy, external beam radiotherapy, radical prostatectomy, primary hormonal therapy, and others (e.g., cryotherapy) (1). To choose from this menu, patients . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
Henry K. Tsai, Anthony V. D’Amico, Natalia Sadetsky, Ming-Hui Chen, and Peter R. Carroll
J Natl Cancer Inst 2007 99: 1516-1524. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 1497. [Extract] [Full Text] [PDF]

Prostate Cancer Therapy Linked to Increased Risk of Heart Disease Death
Liz Savage and Andrea Widener
J Natl Cancer Inst 2007 99: 1497. [Extract] [Full Text] [PDF]